Collaborators and Supporters

We would like to acknowledge and thank our contributors and supporters.

International Society of Pharmacoepidemiology (April 2010)

Contributors have provided periodic consultation and advice:

• Nancy Berkman, RTI International
• Nick Black, London School of Hygiene and Tropical Medicine
• Alan Brookhart, Associate Professor, Department of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health
• Sarah Garner, Research & Development, NICE
• Tobias Gerhard, Ernest Mario School of Pharmacy, Rutgers University
• Kathy Lohr, RTI International
• Newell McElwee, US Outcomes Research, Merck & Co., Inc.
• Barbara McNeil, Health Care Policy, Harvard Medical School
• Peter Neumann, Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Professor, Tufts University School of Medicine
• Dan Ollendorf, Institute for Clinical & Economic Review
• Steve Pearson, President, Institute for Clinical and Economic Review, Massachusetts General Hospital Institute for Technology Assessment
• Sebastian Schneeweiss, Harvard Medical School; Dept. of Medicine, Brigham & Women's Hospital
• Tarang Sharma, Research & Development, NICE
• Daniel Singer, Clinical Epidemiology, Harvard Medical School; Epidemiology, Outcomes, and Disease, Management Unit, MGH Clinical Research Program
• Harold C. Sox, Professor of Medicine (emeritus, active), Dartmouth Medical School; Associate Director for Faculty; The Dartmouth Institute for Health Policy and Clinical Practice
• Brian Sweet, Healthcare Alliances, AstraZeneca
• Sean Tunis, Center for Medical Technology Policy (CMTP)
• Meera Viswanathan, RTI International
• Noel Weiss, Professor of Epidemiology, School of Public Health, University of Washington

• Daniel Ankrah, Korle-Bu Teaching Hospital
• Quazi Ataher, Worldwide Safety Strategy, Pfizer
• Anjan Banerjee, PopeWoodhead & Associates; Institute of Biotechnology, Cambrdige University
• Henny Bang Jakobsen, Medical Sciences, Nycomed: a Takeda Company
• Kathleen Bennett, Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St. James Hospital
• Nirmala Bhoo Pathy, National Clinical Research Centre, Malaysia
• William Blumentals, Shionogi Inc.
• Rachael Boggon, Medicines and Healthcare Products Regulatory Agency, UK
• Denise Boudreau, Pharmacoepidemiology, Group Health Research Institute
• Suzanne Cadarette, Pharmacoepidemiology and Health Services Research, U. of Toronto
• Aisling R Caffrey, Veterans Affairs Medical Center, Providence, Rhode Island
• Tara Chang, Stanford School of Medicine
• Richard Chapell, Outcomes Research, Merck & Co., Inc.
• Yingkai Cheng, Global Patient Safety, Eli Lilly
• Moni Choudhury, Research & Development, NICE
• Preciosa Coloma, Medical Informatics, Erasmus Medical Center
• Nicole Cossrow, Worldwide Market Access, Johnson & Johnson
• Simon Crespi, Merck
• Concetta Crivera, Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC
• CV Damaraju, Biostatistics, Janssen R&D
• Cynthia de Luise, Worldwide Safety Strategy, Pfizer
• Jenny Devenport, Biostatistics, Genentech
• Andrew Eggleston, Reimbursement and Health Economics, Medtronic
• Eric Elkin, Late Phase & Outcomes Research (ILPOR), ICON
• Sherif Eltonsy, University of Montreal
• Efe Eworuke, Department of Pharmaceutical Outcomes and Policy, University of Florida
• Christine Fletcher, Amgen Ltd.
• Joy Frestedt, Clinical Research, Frestedt Incorporated
• Jon Fryzek, Exponent
• Christiane Gasse, National Centre for Register-based Research, Aarhus University, Denmark
• Yvonne Geissbühler, Global Epidemiology, Novartis Pharma AG
• Cynthia Girman, Epidemiology, Merck Research Laboratories
• Lisa Griffin-Vincent, Regulatory & Clinical Research Institute, Inc.
• Joanna Haas, Global Patient Safety and Risk Management, Genzyme
• Jamaiyah Haniff, Clinical Research Centre, Ministry of Health, Malaysia
• Daniel Hartung, Pharmacoeconomics, Oregon State University
• Jinghua He, Pharmacoepidemiology, Merck Research Laboratories
• Kim Heithoff, US Outcomes Research, Merck & Co., Inc.
• Allen H. Heller, Bayer HealthCare Pharmaceuticals
• Ken Hornbuckle, Global Patient Safety, Eli Lilly and Company
• Xing-Yue Huang, Health Economics and Outcomes Research, Forest Research Institute, Inc.
• Krista Huybrechts, Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School
• Mike Ingham, Health Economics & Outcomes Research, Janssen Biotech
• Ralph Insinga, Health Economics and Statistics, Merck Research Laboratories
• Jessica Jalbert, LA-SER Group
• Ani John, Immunology Registries, Genentech
• Juhaeri Juhaeiri, Pharmacoepidemiology, Sanofi-Aventis
• Marmar Kabir-Ahmadi, Epidemiology, Sanofi France
• Bindweep Kaur, Research & Development, NICE
• Xuehua Ke, WellPoint, Inc.
• John Hon Yoon Khee, National Clinical Research Centre, Malaysia
• Matthijs Killian, Cochlear Technological Center, Belgium
• Arun Krishna, Merck
• R.Scott Leslie, MedImpact Healthcare Systems, Inc
• Huifang Liang, Takeda Pharmaceuticals
• Wei Liu, Channing Laboratory, Harvard University
• Jennifer Lund, University of North Carolina, Chapel Hill
• Frank Xiaoqing Liu, Global Health Economics and Outcomes Research, Baxter Healthcare
• Jesus M Lopez Arrieta, Hospital de Cantoblanco
• Peggy Monica McKinnon Crompton, Health Economics and Outcomes Research, Cubist Pharmaceuticals
• Vinay Mehta, Pharmacoepidemiology, Merck
• Laura Menditto, US Health Outcomes, GlaxoSmithKline
• Sharon Meropol, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine
• Shannon Michels, Comprehensive Health Insights-A Humana Company
• Debbie Moritz, Epidemiology, Genentech
• Elaine Morrato, Health Systems, Management and Policy, University of Colorado at Denver
• Joaquin Mould, Health Econ. & Outcomes Res., Latin America & Primary Care Products, Pfizer
• Yuen Mi Yim, Biostatistics, Genentech
• Erwan Muros, Global Medical Science & Communication, Actelion Pharmaceuticals Ltd.
• Lakshmi Murthy, NICE
• Siva Narayanan, Medical Affairs, Human Genome Sciences, Inc.
• Winnie Nelson, Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC
• Jude Nwokike, Management Sciences for Health
• Alexis Ogdie, Rheumatology Division, University of Pennsylvania
• William Olson, Research and Analysis Strategy, Janssen Scientific Affairs, LLC
• Niki Palmetto, Worldwide Safety Strategy, Pfizer
• Mary Panaccio, US Medical Affairs, Sanofi-Aventis
• Jongbae Jay Park, University of North Carolina at Chapel Hill
• Hannah Patrick, NICE
• Federica Pisa, Institute of Hygiene and Clinical Epidemiology, University Hospital of Udine, Italy
• Nicole Pratt, Quality Use of Medicines and Pharmacy Resarch Centre, University of South Australia
• Donald R. Miller, Epidemiology and Health Services Research, Boston University
• Diane Randall, CNS Operations, Bristol-Myers Squibb
• Cristina Rebordosa, Novartis
• Valencia Remple, Health Economics & Outcomes Research, Pfizer
• Evelyn Rodriguez, Bracco Diagnostics Inc.
• Karie Rosolowski, American Society of Plastic Surgeons
• Matthew Rousculp, Comparative Effectiveness Research, GlaxoSmithKline
• Shiva Sajjan, Merck
• Grannum Sant, Sanofi-Aventis
• Tania Schink, Prevention Research and Epidemiology, BIPS
• Amy P. Sing, Genomic Health
• Jim Slattery, Pharmacovigilance and Risk Management, European Medicines Agency
• Patricia Splett, Department of Food Science and Nutrition, University of Minnesota
• Paul Stang, Epidemiology, Johnson & Johnson Pharmaceutical Research and Development
• Julio E Vazquez Suarez, Eli Lilly, Puerto Rico
• Sarah T. Tonn, Clinical Quality and Performance Evaluation, American Academy of Neurology
• Iris Tam, Managed Care Medical Communications, Genentech
• Boxiong Tang, Outcomes Research, Pfizer Inc.
• Thang Tran, Health Economics & Outcomes Research, Pfizer
• Hanae Ueyama, Department of Pharmacoepidemiology, Kyoto University
• Luis Veloso, Eurotrials
• Patrice Verpillat, Global Market Access and Pricing Strategies, Sanofi-Aventis
• Naunihal S. Virdi, Medical Affairs, LifeScan
• Ute Weisgerber-Kriegl, Hoffmann-La Roche Ltd
• Grace West, Global Statistical Science, Amgen Inc.
• Chuntao Wu, Sanofi
• Seet Wymen, Clinical Research Centre, Ministry of Health, Malaysia
• Fei Xue, Amgen Inc.
• Yuer Yan, Global Patient Safety, Eli Lilly
• Yea-Huei Kao Yang, Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Taiwan
• Huiying Yang, Allergan
• Linda Yau, Biometrics & Health Outcomes and Payer Support, US Medical Affairs, Genentech
• Mellissa Yong, Global Epidemiology, Amgen, Inc.
• Marianne Yood, EpiSource
• Shengsheng Yu, Merck
• Jie Zhang, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corp.
• Helga Zoega, Mt. Sinai Medical Center

• José Luis Alloza, Dep. de Farmacología-Facultad de Medicina, The U. of Alcalá, Madrid, Spain
• G. Lawrence Atkins, Public Policy and Reimbursement, Schering-Plough
• Jesse Berlin, Pharmacoepidemiology, J&J Pharmaceutical R&D
• Michael N. Cook, Global Safety Surveillance & Epidemiology, Pfizer
• Christina Farup, Evidence Based Medicine, Novartis
• Dale Glasser, Consultant
• Richard Gliklich, President, Quintiles Outcome
• R.M.C. Herings, Dpt of Health Policy and Mgmt, Erasmus MC. Rotterdam, The Netherlands
• Ken Hornbuckle, Risk Management & Pharmacoepidemiology, Eli Lilly
• Mark V. Johnston, College of Health Sciences. University of Wisconsin
• Kristijan Kahler, HE&R, ABGU & NS Evidence Based Medicine, Novartis
• Stephen Motsko, Risk Management & Pharmacoepidemiology, Eli Lilly
• John Parkinson, Clinical Practice Research Datalink
• Jeff Schein, Scientific Affairs, Ortho-McNeil Janssen
• Hemal Shah, Health Economics & Outcomes Res., Boehringer Ingelheim Pharmaceuticals, Inc.
• J. Michael Sprafka, Amgen
• Til Stürmer, Dept. of Epidemiology, U. of North Carolina, School of Public Health, Chapel Hill
• Alexander M. Walker, Principal, Whiscon
• Douglas J. Watson, Medical/Scientific Liaison, Merck Research Laboratories